It may be possible that the extent of Bim upregulation was not able to overcome the high rate of BCL2 overexpression seen in MCL and combining otlertuzumab with a BH3 mimetic, such as venetoclax, may offer much better responses. Here, BCL2 is linked to mantle cell lymphoma.